Heron CFO acquires 11,695 shares via RSUs

Heron Therapeutics EVP and CFO Ira Duarte reported an automatic conversion of restricted stock units into common shares.

Rhea-AI Filing Summary

Heron Therapeutics EVP and CFO Ira Duarte reported an automatic conversion of restricted stock units into common shares. On January 31, 2026, 11,695 restricted stock units were converted into 11,695 shares of common stock at a price of $0 per share under a previously granted equity award.

After this transaction, Duarte directly owned 195,356 shares of common stock and held 140,332 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 16 equal quarterly installments that began on January 31, 2025.

Insider Trade Summary

11,695 shares exercised/converted

Exercise 2 txns

Insider Duarte Ira

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	11,695	$0.00	$0.00
Exercise	Common Stock	11,695	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 140,332 contracts (Direct); Common Stock — 195,356 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. F2. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Heron Therapeutics (HRTX) report for Ira Duarte?

Heron Therapeutics reported that EVP and CFO Ira Duarte had 11,695 restricted stock units convert into 11,695 shares of common stock at $0 per share on January 31, 2026, under a previously granted equity award.

How many Heron Therapeutics (HRTX) shares does Ira Duarte own after this Form 4?

After the reported transaction, Ira Duarte directly owns 195,356 shares of Heron Therapeutics common stock. This reflects the addition of 11,695 shares received from the conversion of restricted stock units on January 31, 2026.

What happened to Ira Duarte’s restricted stock units in this Heron (HRTX) filing?

In this filing, 11,695 restricted stock units held by Ira Duarte were converted into 11,695 shares of common stock. Each restricted stock unit represents a right to one share, and the award vests in 16 equal quarterly installments.

How many restricted stock units does Ira Duarte hold after the Heron (HRTX) transaction?

Following the conversion, Ira Duarte holds 140,332 restricted stock units. These units vest in 16 equal installments that began one quarter after the January 31, 2025 grant date, providing future share deliveries over the vesting schedule.

What does transaction code "M" mean in the Heron Therapeutics (HRTX) Form 4?

Transaction code “M” indicates an exercise or conversion of a derivative security, such as restricted stock units. Here, it reflects the automatic conversion of 11,695 restricted stock units into 11,695 shares of Heron Therapeutics common stock at $0 per share.

What is the vesting schedule for Ira Duarte’s Heron (HRTX) restricted stock units?

The restricted stock units vest in 16 equal installments, beginning one quarter after the grant date of January 31, 2025. This means Duarte receives additional common shares over time as each quarterly vesting installment is satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 08:30 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duarte Ira

(Last) (First) (Middle)

100 REGENCY FOREST DRIVE

SUITE 300

(Street)

CARY NC 27518

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		11,695	A	(1)	195,356	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	01/31/2026		M			11,695	(2)	(2)	Common Stock	11,695	$0	140,332	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

	/s/Kathryn Lester Attorney-in-fact for Ira Duarte	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.